← Leaderboards
Xue-Zhong Yu
Medical College Of Wisconsin
$18,834,259
Attributed
$19,857,259
Total exposure
15
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$19,857,259 · 15
By mechanism
R01$17,859,279 · 10
R21$1,408,883 · 4
K01$589,097 · 1
Top collaborators
- Amer Aziz Beg5 shared
Most similar at Medical College Of Wisconsin
Same institution · by research overlap
- William R. Drobyski$18,734,918
- Ashley K Brown$161,206
- Cecilia J Hillard$13,181,596
Others in their field
Top investigators on “T-Lymphocyte”
- Barton F Haynes · Duke University$296,833,570
- Lawrence Corey · Fred Hutchinson Cancer Center$270,341,865
- Dan H. Barouch · Fred Hutchinson Cancer Center$117,305,894
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$107,651,960
- Alessandro Sette · La Jolla Institute For Immunology$75,756,097
- Rama Rao Amara · Emory University$69,530,112
Research focus
T-LymphocyteLeukemiaBone Marrow TransplantationHematopoieticAllogeneic Bone Marrow TransplantationPreventTransplantationMorbidity - Disease RateResponseCellsAllogenicComplicationMalignant - DescriptorMalignant NeoplasmsMediatingTumorMolecularPlayAntigensGraft-Vs-Host DiseaseHematopoietic Cell TransplantationRegulatory T-LymphocyteAlloantigenBenign
Grant awards (59)
Control of GVHD by Probiotics with individual Commensal Bacteria$611,738
R01 · FY2025 · HL · contact PI
Pathogenic role of IL-39/IL-39R signaling in graft-versus-host disease$586,203
R01 · FY2025 · HL · contact PI
Targeting PIM-2 Kinase for Improving Cancer Immunotherapy$538,665
R01 · FY2025 · CA · contact PI
Control of GVHD by Probiotics with individual Commensal Bacteria$599,503
R01 · FY2024 · HL · contact PI
Targeting PIM-2 Kinase for Improving Cancer Immunotherapy$511,800
R01 · FY2024 · CA · contact PI
Control of GVHD by Probiotics with individual Commensal Bacteria$613,542
R01 · FY2023 · HL · contact PI
Targeting PIM-2 Kinase for Improving Cancer Immunotherapy$528,033
R01 · FY2023 · CA · contact PI
ER stress pathways regulate T-cell allogeneic and anti-tumor responses$178,679
R21 · FY2023 · CA · contact PI
Control of GVHD by Probiotics with individual Commensal Bacteria$623,934
R01 · FY2022 · HL · contact PI
Targeting PIM-2 Kinase for Improving Cancer Immunotherapy$552,877
R01 · FY2022 · CA · contact PI
ER stress pathways regulate T-cell allogeneic and anti-tumor responses$218,790
R21 · FY2022 · CA · contact PI
Targeting IRE-1a/XBP-1 Axis for Control of Chronic GVHD and Leukemia Relapse$512,788
R01 · FY2021 · HL · contact PI
Targeting IRE-1a/XBP-1 Axis for Control of Chronic GVHD and Leukemia Relapse$72,779
R01 · FY2021 · HL · contact PI
Targeting IRE-1a/XBP-1 Axis for Control of Chronic GVHD and Leukemia Relapse$588,114
R01 · FY2020 · HL · contact PI
Separation of GVH and GVL Responses Using Alloreactive CD8 iTregs$375,032
R01 · FY2020 · HL · contact PI
Targeting IRE-1a/XBP-1 Axis for Control of Chronic GVHD and Leukemia Relapse$590,612
R01 · FY2019 · HL · contact PI
Separation of GVH and GVL Responses Using Alloreactive CD8 iTregs$375,032
R01 · FY2019 · HL · contact PI
MicroRNA Regulates Graft-versus-Host Disease$364,240
R01 · FY2019 · AI · contact PI
Ceramide Synthesis as a Potential Target for Control of GVHD$186,875
R21 · FY2019 · AI · contact PI
Targeting IRE-1a/XBP-1 Axis for Control of Chronic GVHD and Leukemia Relapse$602,961
R01 · FY2018 · HL · contact PI
Separation of GVH and GVL Responses Using Alloreactive CD8 iTregs$376,785
R01 · FY2018 · HL · contact PI
MicroRNA Regulates Graft-versus-Host Disease$366,977
R01 · FY2018 · AI · contact PI
Ceramide Synthesis as a Potential Target for Control of GVHD$224,250
R21 · FY2018 · AI · contact PI
Separation of GVH and GVL Responses Using Alloreactive CD8 iTregs$385,655
R01 · FY2017 · HL · contact PI
MicroRNA Regulates Graft-versus-Host Disease$371,988
R01 · FY2017 · AI · contact PI
Targeting IL-12/23 p40 Pathways for the Control of GVHD$314,378
R01 · FY2017 · CA · contact PI
MicroRNA Regulates Graft-versus-Host Disease$373,750
R01 · FY2016 · AI · contact PI
Targeting IL-12/23 p40 Pathways for the Control of GVHD$314,378
R01 · FY2016 · CA · contact PI
Control of GVHD and Leukemia Relapse by Targeting Cell Metabolism$162,581
R21 · FY2016 · CA · contact PI
Targeting IL-12/23 p40 Pathways for the Control of GVHD$314,378
R01 · FY2015 · CA · contact PI
Alloreactive Regulatory T cells control GVHD and maintain GVL effect$264,033
R01 · FY2015 · CA · contact PI
Control of GVHD and Leukemia Relapse by Targeting Cell Metabolism$195,098
R21 · FY2015 · CA · contact PI
MicroRNA Regulates Graft-versus-Host Disease$186,875
R01 · FY2015 · AI · contact PI
Elucidating the Function of PKC-theta in Alloreactivity and GVHD$413,325
R01 · FY2014 · AI
Targeting IL-12/23 p40 Pathways for the Control of GVHD$304,946
R01 · FY2014 · CA · contact PI
Alloreactive Regulatory T cells control GVHD and maintain GVL effect$256,112
R01 · FY2014 · CA · contact PI
Elucidating the Function of PKC-theta in Alloreactivity and GVHD$388,526
R01 · FY2013 · AI
Th1/Th17 Cell Differentiation in GVHD and GVL$293,729
R01 · FY2013 · CA · contact PI
Alloreactive Regulatory T cells control GVHD and maintain GVL effect$248,131
R01 · FY2013 · CA · contact PI
Targeting IL-12/23 p40 Pathways for the Control of GVHD$207,107
R01 · FY2013 · CA · contact PI
Targeting IL-12/23 p40 Pathways for the Control of GVHD$133,678
R01 · FY2013 · CA · contact PI
Elucidating the Function of PKC-theta in Alloreactivity and GVHD$413,325
R01 · FY2012 · AI
Th1/Th17 Cell Differentiation in GVHD and GVL$341,867
R01 · FY2012 · CA · contact PI
Alloreactive Regulatory T cells control GVHD and maintain GVL effect$291,425
R01 · FY2012 · CA · contact PI
Elucidating the Function of PKC-theta in Alloreactivity and GVHD$413,325
R01 · FY2011 · AI
Th1/Th17 Cell Differentiation in GVHD and GVL$333,323
R01 · FY2011 · CA · contact PI
Alloreactive Regulatory T cells control GVHD and maintain GVL effect$291,425
R01 · FY2011 · CA · contact PI
Elucidating the Function of PKC-theta in Alloreactivity and GVHD$417,500
R01 · FY2010 · AI
Th1/Th17 Cell Differentiation in GVHD and GVL$343,632
R01 · FY2010 · CA · contact PI
Effects of Foxp3-Induced Regulatory T Cells on GVHD and GVT Activity$286,106
R01 · FY2008 · CA · contact PI
Effects of Foxp3-Induced Regulatory T Cells on GVHD and GVT Activity$278,329
R01 · FY2007 · CA · contact PI
Effects of Foxp3-Induced Regulatory T Cells on GVHD and GVT Activity$286,418
R01 · FY2006 · CA · contact PI
Control of GVHD by Inducible T-Regulatory Cells$242,610
R21 · FY2005 · AI
ALLO SPECIFIC TOLERANCE BY TARGETING CD28$88,350
K01 · FY2004 · CA
ALLO SPECIFIC TOLERANCE BY TARGETING CD28$57,641
K01 · FY2004 · CA
ALLO SPECIFIC TOLERANCE BY TARGETING CD28$140,376
K01 · FY2003 · CA
ALLO SPECIFIC TOLERANCE BY TARGETING CD28$134,785
K01 · FY2002 · CA
ALLO SPECIFIC TOLERANCE BY TARGETING CD28$85,619
K01 · FY2001 · CA
ALLO SPECIFIC TOLERANCE BY TARGETING CD28$82,326
K01 · FY2000 · CA